TY - JOUR
T1 - Immunotherapy in prostate cancer
T2 - current state and future perspectives
AU - Handa, Shivani
AU - Hans, Bandhul
AU - Goel, Shokhi
AU - Bashorun, Hafis O.
AU - Dovey, Zach
AU - Tewari, Ashutosh
N1 - Publisher Copyright:
© The Author(s), 2020.
PY - 2020
Y1 - 2020
N2 - Metastatic castrate resistant prostate cancer (PCa) remains an incurable entity. In the era of immunotherapy, the complex PCa microenvironment poses a unique challenge to the successful application of this class of agents. However, in the last decade, a tremendous effort has been made to explore this field of therapeutics. In this review, the physiology of the cancer immunity cycle is highlighted in the context of the prostate tumor microenvironment, and the current evidence for use of various classes of immunotherapy agents including vaccines (dendritic cell based, viral vector based and DNA/mRNA based), immune checkpoint inhibitors, Chimeric antigen receptor T cell therapy, antibody-mediated radioimmunotherapy, antibody drug conjugates, and bispecific antibodies, is consolidated. Finally, the future directions for combinatorial approaches to combat PCa are discussed.
AB - Metastatic castrate resistant prostate cancer (PCa) remains an incurable entity. In the era of immunotherapy, the complex PCa microenvironment poses a unique challenge to the successful application of this class of agents. However, in the last decade, a tremendous effort has been made to explore this field of therapeutics. In this review, the physiology of the cancer immunity cycle is highlighted in the context of the prostate tumor microenvironment, and the current evidence for use of various classes of immunotherapy agents including vaccines (dendritic cell based, viral vector based and DNA/mRNA based), immune checkpoint inhibitors, Chimeric antigen receptor T cell therapy, antibody-mediated radioimmunotherapy, antibody drug conjugates, and bispecific antibodies, is consolidated. Finally, the future directions for combinatorial approaches to combat PCa are discussed.
KW - CAR-T cell
KW - Prostate cancer
KW - Sipuleucel-T
KW - adoptive cell therapy
KW - cancer vaccines
KW - cancer-immunity cycle
KW - immune checkpoint inhibitor
KW - immunotherapy
KW - metastatic castration resistant prostate cancer
KW - radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85090183242&partnerID=8YFLogxK
U2 - 10.1177/1756287220951404
DO - 10.1177/1756287220951404
M3 - Review article
AN - SCOPUS:85090183242
SN - 1756-2872
VL - 12
JO - Therapeutic Advances in Urology
JF - Therapeutic Advances in Urology
ER -